<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00498628</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAA_DTRR-2007-LITTEN-01</org_study_id>
    <nct_id>NCT00498628</nct_id>
  </id_info>
  <brief_title>Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency</brief_title>
  <official_title>A Phase 2, Double-Blind, Placebo Controlled Trial to Assess the Efficacy of Quetiapine Fumarate Extended Release for the Treatment of Alcohol Dependence in Very Heavy Drinkers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether quetiapine fumarate extended release is
      effective in the treatment of alcohol dependence in very heavy drinkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate quetiapine fumarate XR (SEROQUEL XR®), a dibenzothiazepine
      derivative, as a potential medication for treating alcohol dependence. The immediate release
      form of quetiapine fumarate, SEROQUEL XR®, is approved by the FDA for treatment of
      schizophrenia and acute manic episodes associated with bipolar disorder. The extended release
      formulation (SEROQUEL XR®) is also approved by the FDA and is undergoing clinical
      investigation for the treatment of major depressive disorders, schizophrenia, generalized
      anxiety disorder, and alcohol dependence.

      Treatment with other atypical antipsychotics such as clozapine and olanzapine has resulted in
      decreases in alcohol use in alcohol dependent patients with and without comorbid psychiatric
      diagnoses. Quetiapine, like clozapine, appears to have efficacy in reducing drug and alcohol
      use among alcoholics and drug dependent patients with co-morbid psychiatric illness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Heavy Drinking Days</measure>
    <time_frame>Weeks 3 - 11</time_frame>
    <description>A heavy drinking day is defined as 5 or more drinks for men and 4 or more drinks for women during a 24 hour period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Days Abstinent</measure>
    <time_frame>3-11</time_frame>
    <description>Percentage of days abstinent (PDA) between Study Days 15 and 77</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drinks Per Drinking Day</measure>
    <time_frame>3-11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drinks Per Day</measure>
    <time_frame>3-11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Very Heavy Drinking Day</measure>
    <time_frame>3-11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Subjects Abstinent</measure>
    <time_frame>3-11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Subjects With no Heavy Drinking Day</measure>
    <time_frame>3-11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drinking Consequences Score</measure>
    <time_frame>Weeks 6 and 12</time_frame>
    <description>Drinkers Inventory of Consequences (DrInC) - Alcohol-related problems are determined using the DrInC (Miller et al., 1995). The DrInC is a self-administered 50-item questionnaire designed to measure adverse consequences of alcohol abuse in five areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. Each scale provides a lifetime and past 3-month measure of adverse consequences, and scales can be combined to assess total adverse consequences. At baseline the DrInC-2R will be used to assess the 90-day period prior to baseline. For weeks 6 and 12, the DrInC-2R will be used, but will be modified to assess alcohol-related problems over the previous 6-week period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penn Alcohol Craving Score (PACS_</measure>
    <time_frame>Week 4, 6, 8, 10, 12</time_frame>
    <description>The Penn Alcohol Craving Scale (PACS) is a five-item, self-report measure that includes questions about the frequency, intensity, and duration of craving, the ability to resist drinking, and asks for an overall rating of craving for alcohol for the previous week (Flannery et al., 1999). Based on clinical study results, the PACS have been shown to be a reliable and valid measure of alcohol craving and can predict subjects at risk for subsequent relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Week 4, 6, 8, 10, and 12</time_frame>
    <description>The MADRS is an observer rating scale that has proven to be an efficient and practical measure of depression (Montgomery and Asberg, 1979). The scale was constructed to be sensitive to changes in treatment effects. Its capacity to differentiate between responders and non-responders to antidepressant treatment has been shown to be comparable to the Hamilton Rating Scale for Depression, another established measure of depressive symptomatology, but the MADRS has greater sensitivity to change during the course of a depressive phase. It has exhibited high inter-rater reliability and appears to be oriented more towards psychic as opposed to somatic aspects of depression. The MADRS is a 10-item checklist where items are rated on a scale of 0 to 6 with anchors at 2-point intervals. Scores range from 0 to 60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Scale (HAM-A)</measure>
    <time_frame>Weeks 4, 6, 8, 10 and 12</time_frame>
    <description>The Hamilton Anxiety Scale consists of 14 items, each defined by a series of symptoms. Similar to the HAM-D, each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe). (Guy, 1976).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality Score</measure>
    <time_frame>Weeks 4, 8 and 12</time_frame>
    <description>The Pittsburgh Sleep Quality Index is a 19-item questionnaire with seven sub scales (subjective sleep quality, sleep latency, sleep duration, habitual sleep disturbances, use of sleep medication and day time dysfunction) (Buysse et al., 1989). Each sub-scale is rated from 0-3 with the higher scores reflecting more severe sleep complaints. The addition of all the scores permits an analysis of the subject's overall sleep experience in the past 30 days. The lower the overall score, the better the person sleeps. The tool has an adequate internal reliability, validity and consistency for clinical and community samples of the various populations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life SF - 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The SF-12 will be used to assess overall health status. The SF-12 is a 12-item questionnaire developed in 1994 as a shorter alternative to the SF-36 to reproduce the physical and mental health summary measures with at least 90% accuracy and allows for calculation of the physical and mental component summary scores.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Alcoholism</condition>
  <condition>Alcohol Abuse</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine fumarate plus medical management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Medical management plus placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine fumarate</intervention_name>
    <description>Quetiapine fumarate- taken daily, for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>SEROQUEL XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between the ages of 18 and 65 years old

          -  DSM-IV diagnosis of current alcohol dependence as supported by SCID Module E

          -  Report &quot;very heavy&quot; drinking (10 or more drinks per drinking day for men or 8 or more
             drinks per drinking day for women) at least 40% of the days during the interval from
             day 31 to 90 prior to the initial screening visit (i.e. a total of 24 days of this
             60-day period), with at least one day of &quot;very heavy&quot; drinking occurring within the
             last 2 weeks before screening

          -  Seeking treatment for alcohol dependence and desire reduction or cessation of drinking

          -  Able to verbalize understanding of the consent form, able to provide written informed
             consent, and verbalize willingness to complete study procedures

          -  Females of child bearing potential must agree to use of at least one approved method
             of birth control, or must be surgically sterile or postmenopausal

          -  Able to take oral medication, willing to adhere to the medication regimen, and willing
             to return for regular visits

          -  Able to understand written and oral instructions in English and to complete the
             questionnaires required by the protocol

          -  Can complete all psychological assessments required at screening and baseline

          -  Able to provide evidence of stable residence in the last 2 months prior to
             randomization, have reasonable transportation arrangements to study site, and have no
             plans to move within the next 3 months or unresolved legal problems; must provide
             contact information of family member, spouse, or significant other who can contact
             subject in case of missed appointment

          -  Breath alcohol concentration (BAC) equal to 0.00 when s/he signed the informed consent
             document

          -  Must have an absolute neutrophil count of 1.5 x 109/L or greater.

        Exclusion Criteria:

        Please contact site for additional information.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raye Z. Litten, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margaret E. Mattson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joanne Fertig, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University School of Medicine, Psychiatry Clinical Studies Unit</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Medical School, Dept. of Psychiatry</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Treatment Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University Center for Alcohol and Addiction Studies</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>12906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>White River Junction VA Medical Center</name>
      <address>
        <city>White River Junction</city>
        <state>Vermont</state>
        <zip>05009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia, Dept. of Psychiatric Medicine</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NA, Kampman K, Stout R; NCIG 001 Study Group. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012 Mar;36(3):406-16. doi: 10.1111/j.1530-0277.2011.01649.x. Epub 2011 Sep 26.</citation>
    <PMID>21950727</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2007</study_first_submitted>
  <study_first_submitted_qc>July 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2007</study_first_posted>
  <results_first_submitted>April 25, 2012</results_first_submitted>
  <results_first_submitted_qc>April 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 30, 2012</results_first_posted>
  <disposition_first_submitted>February 10, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>March 2, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 16, 2011</disposition_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcoholism</keyword>
  <keyword>Alcohol dependence</keyword>
  <keyword>Quetiapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Interested candidates responded by telephone to advertisements at 5 academic centers in the United States between December 2007 and May 2009.</recruitment_details>
      <pre_assignment_details>218 comprises the Modified Intent To Treat group (MITT)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Quetiapine Fumerate Plus Medical Management</title>
          <description>Quetiapine fumarate - target dose 400mg/day plus medical management</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill Plus Medical Management</title>
          <description>Medical management plus placebo comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Quetiapine Fumerate Plus Medical Management</title>
          <description>Quetiapine fumarate - target dose 400mg/day plus medical management</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill Plus Medical Management</title>
          <description>Medical management plus placebo comparator</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
            <count group_id="B2" value="113"/>
            <count group_id="B3" value="218"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="218"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.4" spread="9.3"/>
                    <measurement group_id="B2" value="45.5" spread="9.8"/>
                    <measurement group_id="B3" value="45.4" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Heavy Drinking Days</title>
        <description>A heavy drinking day is defined as 5 or more drinks for men and 4 or more drinks for women during a 24 hour period.</description>
        <time_frame>Weeks 3 - 11</time_frame>
        <population>Intention to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine Fumerate Plus Medical Management</title>
            <description>Quetiapine fumarate - target dose 400mg/day plus medical management</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill Plus Medical Management</title>
            <description>Medical management plus placebo comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Heavy Drinking Days</title>
          <description>A heavy drinking day is defined as 5 or more drinks for men and 4 or more drinks for women during a 24 hour period.</description>
          <population>Intention to Treat</population>
          <units>percentage of heavy drinking days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" spread="3.5"/>
                    <measurement group_id="O2" value="37.9" spread="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Days Abstinent</title>
        <description>Percentage of days abstinent (PDA) between Study Days 15 and 77</description>
        <time_frame>3-11</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drinks Per Drinking Day</title>
        <time_frame>3-11</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drinks Per Day</title>
        <time_frame>3-11</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Very Heavy Drinking Day</title>
        <time_frame>3-11</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Subjects Abstinent</title>
        <time_frame>3-11</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Subjects With no Heavy Drinking Day</title>
        <time_frame>3-11</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drinking Consequences Score</title>
        <description>Drinkers Inventory of Consequences (DrInC) - Alcohol-related problems are determined using the DrInC (Miller et al., 1995). The DrInC is a self-administered 50-item questionnaire designed to measure adverse consequences of alcohol abuse in five areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. Each scale provides a lifetime and past 3-month measure of adverse consequences, and scales can be combined to assess total adverse consequences. At baseline the DrInC-2R will be used to assess the 90-day period prior to baseline. For weeks 6 and 12, the DrInC-2R will be used, but will be modified to assess alcohol-related problems over the previous 6-week period.</description>
        <time_frame>Weeks 6 and 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Penn Alcohol Craving Score (PACS_</title>
        <description>The Penn Alcohol Craving Scale (PACS) is a five-item, self-report measure that includes questions about the frequency, intensity, and duration of craving, the ability to resist drinking, and asks for an overall rating of craving for alcohol for the previous week (Flannery et al., 1999). Based on clinical study results, the PACS have been shown to be a reliable and valid measure of alcohol craving and can predict subjects at risk for subsequent relapse.</description>
        <time_frame>Week 4, 6, 8, 10, 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montgomery-Asberg Depression Rating Scale (MADRS)</title>
        <description>The MADRS is an observer rating scale that has proven to be an efficient and practical measure of depression (Montgomery and Asberg, 1979). The scale was constructed to be sensitive to changes in treatment effects. Its capacity to differentiate between responders and non-responders to antidepressant treatment has been shown to be comparable to the Hamilton Rating Scale for Depression, another established measure of depressive symptomatology, but the MADRS has greater sensitivity to change during the course of a depressive phase. It has exhibited high inter-rater reliability and appears to be oriented more towards psychic as opposed to somatic aspects of depression. The MADRS is a 10-item checklist where items are rated on a scale of 0 to 6 with anchors at 2-point intervals. Scores range from 0 to 60.</description>
        <time_frame>Week 4, 6, 8, 10, and 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Anxiety Scale (HAM-A)</title>
        <description>The Hamilton Anxiety Scale consists of 14 items, each defined by a series of symptoms. Similar to the HAM-D, each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe). (Guy, 1976).</description>
        <time_frame>Weeks 4, 6, 8, 10 and 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality Score</title>
        <description>The Pittsburgh Sleep Quality Index is a 19-item questionnaire with seven sub scales (subjective sleep quality, sleep latency, sleep duration, habitual sleep disturbances, use of sleep medication and day time dysfunction) (Buysse et al., 1989). Each sub-scale is rated from 0–3 with the higher scores reflecting more severe sleep complaints. The addition of all the scores permits an analysis of the subject’s overall sleep experience in the past 30 days. The lower the overall score, the better the person sleeps. The tool has an adequate internal reliability, validity and consistency for clinical and community samples of the various populations.</description>
        <time_frame>Weeks 4, 8 and 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life SF - 12</title>
        <description>The SF-12 will be used to assess overall health status. The SF-12 is a 12-item questionnaire developed in 1994 as a shorter alternative to the SF-36 to reproduce the physical and mental health summary measures with at least 90% accuracy and allows for calculation of the physical and mental component summary scores.</description>
        <time_frame>Week 12</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Systematic assessment at each clinic visit and telephone contact in response to the question &quot;How have you been feeling since the last time we spoke?&quot;</desc>
      <group_list>
        <group group_id="E1">
          <title>Quetiapine Fumerate Plus Medical Management</title>
          <description>Quetiapine fumarate - target dose 400mg/day plus medical management</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill Plus Medical Management</title>
          <description>Medical management plus placebo comparator</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Ruptured Spleen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pre-ventricular contractions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Automobile Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol Detoxification</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Behavioral Disturbance while intoxicated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="36" subjects_affected="34" subjects_at_risk="105"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="14" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="105"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="105"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="29" subjects_affected="22" subjects_at_risk="105"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Feeling Abnormal</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="105"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="105"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Mylagia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="105"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="105"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Somnelence</sub_title>
                <counts group_id="E1" events="42" subjects_affected="36" subjects_at_risk="105"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="60" subjects_affected="36" subjects_at_risk="105"/>
                <counts group_id="E2" events="83" subjects_affected="49" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="105"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="26" subjects_affected="20" subjects_at_risk="105"/>
                <counts group_id="E2" events="33" subjects_affected="25" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="105"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Depressed Mood</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Abnormal Dreams</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="105"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="105"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="105"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Oropharynageal Pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Raye Litten</name_or_title>
      <organization>NIAAA</organization>
      <phone>301-443-0636</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

